PL1842534T3 - Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania - Google Patents

Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania

Info

Publication number
PL1842534T3
PL1842534T3 PL06252598T PL06252598T PL1842534T3 PL 1842534 T3 PL1842534 T3 PL 1842534T3 PL 06252598 T PL06252598 T PL 06252598T PL 06252598 T PL06252598 T PL 06252598T PL 1842534 T3 PL1842534 T3 PL 1842534T3
Authority
PL
Poland
Prior art keywords
extended release
methods
preparation
metoprolol succinate
release tablets
Prior art date
Application number
PL06252598T
Other languages
English (en)
Inventor
Tomer Gold
Nava Shterman
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL1842534T3 publication Critical patent/PL1842534T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL06252598T 2006-02-24 2006-05-18 Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania PL1842534T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77670606P 2006-02-24 2006-02-24
EP06252598A EP1842534B1 (en) 2006-02-24 2006-05-18 Metoprolol succinate extended release tablets and methods for their preparation

Publications (1)

Publication Number Publication Date
PL1842534T3 true PL1842534T3 (pl) 2012-05-31

Family

ID=36928616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06252598T PL1842534T3 (pl) 2006-02-24 2006-05-18 Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania

Country Status (13)

Country Link
US (1) US20070202172A1 (pl)
EP (1) EP1842534B1 (pl)
JP (1) JP2009527554A (pl)
KR (1) KR20080099334A (pl)
CN (1) CN101516356A (pl)
AT (1) ATE536864T1 (pl)
BR (1) BRPI0621397A2 (pl)
CA (1) CA2642340A1 (pl)
IL (1) IL193357A0 (pl)
MX (1) MX2008010877A (pl)
PL (1) PL1842534T3 (pl)
RU (1) RU2008136766A (pl)
WO (1) WO2007097770A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3184526T (pt) 2005-12-13 2018-12-19 Incyte Holdings Corp Derivados de pirrolo[2,3-d]pirimidina como inibidores da cinase janus
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
FR2936709B1 (fr) * 2008-10-02 2012-05-11 Ethypharm Sa Comprimes alcoolo-resistants.
EP2255791B1 (en) * 2009-04-03 2011-11-16 Zaklady Farmaceutyczne Polpharma SA Extended release pharmaceutical composition comprising metoprolol succinate
CN102008457B (zh) * 2009-09-04 2014-04-02 北京天衡药物研究院 酒石酸美托洛尔骨架缓释片
JP2013515783A (ja) * 2009-12-29 2013-05-09 インパックス ラボラトリーズ，インコーポレーテッド 膨潤性親水性ポリマーを用いた胃滞留型固体経口投与剤形
CN101773482B (zh) * 2009-12-30 2012-04-25 中国科学院上海药物研究所 一种三段式脉冲释药控释片及其制备方法
TWI766281B (zh) 2010-03-10 2022-06-01 美商英塞特控股公司 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
CN103655480B (zh) * 2012-09-14 2016-12-21 中国人民解放军军事医学科学院毒物药物研究所 一种美托洛尔的缓释药物及其制备方法
SG11201503695XA (en) 2012-11-15 2015-06-29 Incyte Corp Sustained-release dosage forms of ruxolitinib
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
EP3428184A1 (en) * 2017-07-09 2019-01-16 Universitätsklinikum Hamburg-Eppendorf Means for treating cardiovascular disease
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
CN111419813A (zh) * 2020-05-09 2020-07-17 深圳市道科思医药有限公司 一种琥珀酸美托洛尔的缓释片剂及其制备方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022074681A1 (en) * 2020-10-08 2022-04-14 Harman Finochem Limited Pharmaceutical compositions with enhanced blend uniformity and content uniformity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
JPH0819003B2 (ja) * 1988-09-27 1996-02-28 武田薬品工業株式会社 有核顆粒およびその製造法
JP3453186B2 (ja) * 1994-04-14 2003-10-06 共和薬品工業株式会社 徐放性マイクロカプセルおよびその製造方法
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US9358214B2 (en) * 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
MXPA06004700A (es) * 2003-10-31 2006-07-05 Hexal Ag Formulacion conteniendo agente farmaceutico comprendiendo un recubrimiento.
DE10353186A1 (de) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
WO2005084636A2 (en) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited A process for the preparation of controlled-release pharmaceutical composition of metoprolol
US20060204575A1 (en) * 2005-03-11 2006-09-14 Hengsheng Feng Amphetamine formulations

Also Published As

Publication number Publication date
ATE536864T1 (de) 2011-12-15
BRPI0621397A2 (pt) 2012-04-17
IL193357A0 (en) 2009-05-04
CN101516356A (zh) 2009-08-26
RU2008136766A (ru) 2010-03-27
CA2642340A1 (en) 2007-08-30
MX2008010877A (es) 2008-11-25
EP1842534B1 (en) 2011-12-14
WO2007097770A1 (en) 2007-08-30
EP1842534A1 (en) 2007-10-10
WO2007097770A8 (en) 2007-12-06
KR20080099334A (ko) 2008-11-12
JP2009527554A (ja) 2009-07-30
US20070202172A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
PL1842534T3 (pl) Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
EP2130552A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
AP2384A (en) 1,2,4,5-tetrahydro-3H-benzazepine compounds, a process for their preparation and pharmaceutical compositions containing them.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2010049454A3 (en) Antimicrobial composition from copepods
IN2012DN02139A (pl)
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
ZA200801478B (en) Drug compositions containing controlled release hypromellose matrices
WO2010049449A3 (en) Novel salts of sunitinib
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
TN2009000510A1 (en) Extended release formulation of nevirapine
IL218525A (en) Compounds 2,1 - Dihydro - 2 - Oxoquinoline Receptor Legendants 5 - 4ht Process for Preparing, Containing and Using Medical Preparations
MX2007013327A (es) Formulaciones de liberacion prolongada.
PT2231598E (pt) Novos derivados diazéniodiolato, processo para a sua preparação e as composições farmacêuticas que os contenham
WO2011014003A3 (en) (+)-3-hydroxymorphinan derivatives as neuroprotectants
WO2009025792A3 (en) Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof
UA94624C2 (uk) Арипіпразолу геміфумарат і спосіб його одержання
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
GB0615105D0 (en) Novel compounds
ZA200806399B (en) Novel pyridinylaminoalkylene- and pyridinyloxyalkylene-cyclopropanamines, process for the preparation thereof and pharmaceutical compositions containing them
WO2009013594A3 (en) Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process